SCHEMBL5064175

SCHEMBL5064175

Cc1nc(Nc2ccc(Cl)cc2)c2nc(C)sc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.47
EGFR P00533 1/20 0.47
KMT2A Q03164 4/20 0.46
TRPV1 Q8NER1 2/20 0.46
MEN1 O00255 3/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 3/20 0.44
GAA P10253 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ADORA3 P0DMS8 2/20 0.42
ADORA2A P29274 2/20 0.42
ADORA1 P30542 2/20 0.42
ADORA2B P29275 1/20 0.42
CDK2 P24941 1/20 0.41
CDK4 P11802 1/20 0.41
NR1I2 O75469 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5061315 0.88 MAPT (0.44) KDRKMT2ATRPV1MEN1ALDH1A1
SCHEMBL5068853 0.85 KDR (0.47) KDRKMT2ATRPV1MEN1ALDH1A1
SCHEMBL5068900 0.85 ADORA3 (0.57) KDREGFRKMT2ATRPV1MEN1
SCHEMBL5065463 0.81 MAPT (0.45) KDRKMT2ATRPV1MEN1ALDH1A1
SCHEMBL5068960 0.80 TRPV1 (0.40) KDREGFRTRPV1ALDH1A1LMNA
SCHEMBL5064108 0.75 TRPV1 (0.41) KDRTRPV1LMNAMAPTRAB9A
SCHEMBL5068972 0.72 TRPV1 (0.53) EGFRKMT2ATRPV1LMNAMAPT
SCHEMBL16604696 0.72 ADORA3 (0.35) GAAADORA3ADORA2AADORA1ADORA2B
SCHEMBL11012250 0.72 KDR (0.48) KDREGFRKMT2AMEN1ALDH1A1
SCHEMBL11013199 0.71 EGFR (0.47) KDREGFRKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US claimed
EP-1731523-A1 THIAZOLOPYRIMIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-12-13 EP claimed
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
EP-1731523-A1 THIAZOLOPYRIMIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269238-A1 Thiazolopyrimidine Derivative FGFR3, FGFR1, ERBB3 KDR 202/4885EGFR 28/4885KMT2A 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.